Compartmentalization of drug resistance-associated mutations in a treatment-naive HIV-infected female

AIDS Research and Human Retroviruses

Volumn 20, Issue 6, 2004, Pages 684-686

  Tirado, Grissell ^a   Jove, Gloria ^a   Kumar, Rakesh ^a   Noel, Richard J ^a   Reyes, Evelyn ^b   Sepulveda, Gladys ^b   Yamamura, Yasuhiro ^a   Kumar, Anil ^a  

^a PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^b Dept of Health Immunology Clinic ^*  (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; EPITOPE; POL PROTEIN; PROTEINASE; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

ADULT; AMINO ACID SEQUENCE; ARTICLE; BLOOD CELL COUNT; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DISEASE COURSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; OUTPATIENT DEPARTMENT; PATIENT REFERRAL; PLASMA; PRIORITY JOURNAL; T LYMPHOCYTE; THRUSH; VAGINA; VIRUS LOAD; VIRUS MUTATION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; CANDIDIASIS, ORAL; CD4 LYMPHOCYTE COUNT; DNA, VIRAL; DRUG RESISTANCE, VIRAL; EPITOPES; FEMALE; GENES, POL; GENES, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VAGINA; VIRAL LOAD;

EID: 3042598891     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/0889222041217509     Document Type: Article

References (11)

1. Sullivan JL: Prevention of mother-to-child transmission of HIV - what next? J Acquir Immune Defic Syndr 2003;34(Suppl. 1):S67-S72.
2. Kuritzkes DR: Resistance to protease inhibitors. J HIV Ther 2002;7:87-91.
3. Richman DD: HIV chemotherapy. Nature 2001;410:995-1001.
4. Kepler TB and Perelson AS: Drug concentration heterogeneity facilitates the evolution of drug resistance. Proc Natl Acad Sci USA 1998;95:11514-11519.
5. Leigh Brown AJ, Frost SD, Mathews WC, et al.: Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 2003;187:683-686.
6. Little SJ, Holte S, Routy JP, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394.
7. Simon V, Vanderhoeven J, Hurley A, et al.: Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002;16:1511-1519.
8. D'Aquila RT, Schapiro JM, Brun-Vezinet F, et al.: Drug resistance mutations in HIV-1. Top HIV Med 2003;11:92-96.
9. Kozal MJ, Shah N, Shen N, et al.: Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996;2:753-759.
10. Sung H, Foley BT, Ahn SH, et al.: Natural polymorphisms of protease in protease inhibitor-naive HIV-1 infected patients in Korea: A novel L63M in subtype B. AIDS Res Hum Retroviruses 2003;19:525-530.
11. Bette K, Brander C, Haynes B, et al.: HIV Molecular Immunology. Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM, 2001.